[topsearch__bar__shortcode]

CytoMed (GDTC): Pre-Market Stock Surge Amid Strategic Moves

[breadcrumb_custom]

Shares of CytoMed Therapeutics Limited (NASDAQ: GDTC) are experiencing a significant uptick in the US stock market. As of the latest pre-market session, GDTC stock has risen by 17.65%, reaching $2.40. This surge follows the company’s announcement of multiple strategic developments.

Acquisition of Cellsafe International’s Assets

CytoMed, through its wholly owned subsidiary IPSC Depository Sdn Bhd, has acquired the license and certain assets of Cellsafe International Sdn Bhd (CISB). This acquisition, valued at approximately RM 2.3 million (US$ 490,000), was financed using internal cash resources.

CISB, a Malaysian cord blood bank currently in liquidation, offers CytoMed significant assets including a cord blood banking license issued by Malaysia’s Ministry of Health, cryopreservation equipment housing over 12,000 cord blood units (CBUs), and two freehold properties totaling 189 square meters.

CytoMed: Harnessing the Potential of γδ T Cells

With exclusive patents and expertise in γδ T cell technology, CytoMed aims to repurpose the cryopreserved CBUs globally, thus transforming the traditional business model of cord blood banking. The goal is to unlock the therapeutic potential of umbilical cord blood, enhancing the company’s strategic capital in developing cytotoxic γδ T cells for cancer treatment.

CytoMed aspires to lead in γδ T cell technology, producing viable γδ T cells from adult peripheral blood mononuclear cells, induced pluripotent stem cells (iPSCs), and eventually, cryopreserved CBUs.

Patent Award for iPSC-derived Hybrid γδ NKT Cells Technology

In another significant development, CytoMed has announced that the Intellectual Property Corporation of Malaysia has granted a patent for its licensed iPSC-derived hybrid γδ NKT cells technology, targeting both solid and hematological cancers.

This new patent expands CytoMed’s tumor-targeting therapy portfolio, complementing existing patents in Japan and China for the same technology. The patent award is timely, given Malaysia’s growing appeal to biomedical innovators amid an aging population and its reputation as a medical tourism hub.

CytoMed’s IPSC-γδ NKT cell program is actively progressing under GMP development, with animal studies set as the next milestone. Through these strategic initiatives, CytoMed Therapeutics Limited continues to advance its position in the field of cancer treatment, leveraging innovative technologies and expanding its intellectual property portfolio.

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest Posts